Condition: Geographic Atrophy secondary to Dry Age-Related Macular Degeneration
Site: The Retina Clinic London, W1G 9AY
Audience: Optometrists, ophthalmologists and referrers
The Retina Clinic London is currently identifying patients who may be suitable for clinical research studies in Geographic Atrophy secondary to Dry Age-Related Macular Degeneration.
Each study is conducted within The Retina Clinic London’s active clinical trials programme, supported by specialist retinal diagnostics, advanced retinal imaging and protocol-led follow-up.
Suitability can only be confirmed following study-specific screening. Participation is voluntary, and study access is not guaranteed.
Current Geographic Atrophy studies
1. Observational study
Treatment method: No investigational treatment
Study type: Observational imaging and monitoring study
This study is designed to observe and monitor Geographic Atrophy secondary to Dry Age-Related Macular Degeneration using protocol-defined assessments and retinal imaging.
Patients may be appropriate for review if they broadly meet the following profile:
- Aged 55 years or older
- Geographic Atrophy secondary to Dry Age
- Related Macular
- Degeneration
- Foveal or extrafoveal Geographic Atrophy
- Measurable Geographic Atrophy on retinal imaging
- Best corrected visual acuity within study range
2. Phase 2 interventional study
Treatment method: Intravitreal injection into the eye
Study type: Double-masked, randomised, sham-controlled
This study is assessing an investigational intravitreal treatment for Geographic Atrophy secondary to Dry Age-Related Macular Degeneration.
An intravitreal injection is an injection delivered into the vitreous, the gel-like substance inside the eye, allowing treatment to reach the retina directly.
Patients may be appropriate for review if they broadly meet the following profile:
- Aged 55 years or older
- Geographic Atrophy secondary to Dry Age-Related Macular Degeneration
- Non-foveal Geographic Atrophy
- Measurable Geographic Atrophy on retinal imaging
- Best corrected visual acuity within study range
- Intraocular pressure within study limits
3. Phase 2 interventional study
Treatment method: Subcutaneous injection
Study type: Masked, placebo-controlled, randomised
This study is assessing an investigational systemic treatment for Geographic Atrophy secondary to Dry Age-Related Macular Degeneration, delivered by subcutaneous injection.
A subcutaneous injection is an injection given under the skin. Screening may include protocol-defined vaccination requirements.
Patients may be appropriate for review if they broadly meet the following profile:
- Aged 60 to 100 years
- Geographic Atrophy secondary to Dry Age-Related Macular Degeneration
- Geographic Atrophy lesion in the macula
- Measurable Geographic Atrophy on retinal imaging
- Best corrected visual acuity within study range
Referral information requested
For efficient pre-screening, please include where available:
- Diagnosis of Geographic Atrophy secondary to Dry Age-Related Macular Degeneration
- Current best corrected visual acuity (if available)
- OCT and fundus autofluorescence imaging (if available)
- Relevant ocular history, including previous injections, retinal laser or retinal surgery
- Relevant systemic history
Referral pathway
Please refer potential candidates to the Clinical Trials team at The Retina Clinic London.
Referrals: clinicaltrialscoordinators@theretinacliniclondon.com
Telephone: +44 (0)20 4548 5310
Website: www.theretinacliniclondon.com
Clinic: 24 Queen Anne Street, London, W1G 9AY
Research Facility: 140 Harley Street, London, W1G 7LB
All clinical trial participation is subject to protocol-specific screening, eligibility criteria and informed consent. Participation is voluntary and access to a study cannot be guaranteed.